Anti-obesity Drugs Market to Touch USD 22.85 Billion in 2030; Strong Demand for Effective Therapeutic Measures to Cure Patient's Health will Facilitate Industry Growth

The global anti-obesity drugs market size is anticipated to display robust growth by reaching USD 22.85 billion by 2030. Fortune Business Insights™ in its report titled "Anti-obesity Drugs Market Size, Share & COVID-19 Impact Analysis, By Type (Prescription Drugs and OTC Drugs), By Distribution Channel (Hospital Pharmacy and Retail and Online Pharmacy), and Regional Forecast, 2023-2030" observes that the market size was USD 2.82 billion in 2022 and reached USD 4.51 billion in 2023. The market is anticipated to witness a CAGR of 26.1% during 2023-2030. Increasing awareness among the population about the dangers of chronic diseases is likely to fuel the market's progress.

VIVUS Introduced Qsymia to Boost its Market Presence

VIVUS, Inc. introduced Qsymia in the Korean market to help patients achieve and maintain their healthy body-mass index. Furthermore, it allows patients to maintain physical activity and reduce harmful diseases such as blood pressure, high cholesterol, and type 2 diabetes.

High Risk of Virus Transmission Hindered Market's Development During COVID-19

Due to the reduction of in-person visits to healthcare professionals, the industry was negatively affected during the COVID-19 outbreak. For instance, due to a decline in the number of hospital visits, COVID-19 hampered the revenues of Saxenda, a product of Novo Nordisk A/S, in major countries such as the U.S. Furthermore, the high risk of virus transmission led to the imposition of strict lockdown worldwide. Moreover, the unavailability of necessary drugs in certain places negatively affects the anti-drug industry. However, the utilization of online pharmacies and the increasing usage of telemedicine have given industries a chance to lower their loss. These factors helped industry growth during the outbreak.

Rising Need for Anti-obesity Drugs to Drive Market Growth

Due to sedentary lifestyle trends and unhealthy diets among the population worldwide, the demand for the product rose effectively. Furthermore, to combat obesity problem, the demand for effective therapeutic measures has surged the need for new anti-obesity drugs in the global market. Several emerging firms are investing heavily in R&D initiatives for the development of anti-obesity medications to provide effective treatments to patients who are suffering from chronic ailments. For instance, in June 2022, Innovent Biologics, Inc. started its second clinical trial for IBI362 to help overweight patients. These factors are likely to propel the anti-obesity drugs market growth.

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/anti-obesity-drugs-market-104783

Key Companies Focus on Strategic Initiatives to Boost their Market Position

The prominent giants operating in the market deploy acquisition tactics to strengthen their businesses. For example, in November 2021, Novo Nordisk proposed a favorable opinion and recommended suitable ways for adults to control obesity problems. It may help the organization to gain a considerable market reach, boost its brand image, and increase its resources. Further, several companies, such as Boehringer Ingelheim and Zealand Pharma A/S, initiated two trials of the GLP-1/glucagon for Non-alcoholic Steatohepatitis (NASH) adults and obese adults to boost their market position.

Notable Industry Development

• February 2022: Pfizer Inc.’s study on oral diabetes medication called glucagon-like peptide-1 receptors was aimed to control the diabetic concerns of patients.

Further Report Findings

• The market in North America was valued at USD 1.91 billion in 2022 and is expected to gain a considerable portion of the global anti-obesity drugs market share during the forecast period. Growing healthcare spending to address the awareness of chronic diseases is expected to fuel the industry's growth.


• Moreover, strong prevalence of the obese population across the region is likely to fuel the industry's growth. According to the study of the National Library of Medicine (NLM) in 2021, it has been found that the annual healthcare costs are high at USD 2,505 for adults, and it has been anticipated that the number will increase from 68.4% for class 1 to 233.6% for class 3.


• In Europe, there are growing investments in digital medical devices across the region to nurture the industry's growth.

List of Key Players Profiled in the Report

• Pfizer Inc. (U.S.)


• Sandoz International GmbH (Novartis AG) (Germany)


• Boehringer Ingelheim International GmbH (Germany)


• Novo Nordisk A/S (Denmark)


• GlaxoSmithKline plc (U.K.)


• VIVUS LLC. (U.S.)


• Currax Pharmaceuticals LLC (U.S.)


• F. Hoffmann-La Roche Ltd (Switzerland)

Table of Segmentation